-
PBS Liposomes as Macrophage-Depletion Controls
2026-10-09
PBS Liposomes are commonly described as blank liposome controls for separating macrophage-depletion effects from effects caused by the liposome carrier. This overview distinguishes supplier claims from published evidence, explains their conceptual role in macrophage studies, and clarifies why the supplied TRPM3 structural study provides useful context for evidence evaluation but does not validate PBS Liposomes or macrophage-depletion applications.
-
Mavorixafor in WHIM Syndrome: Phase 3 Evidence
2026-10-09
The reference Blood commentary examines a placebo-controlled phase 3 trial of oral mavorixafor, a selective CXCR4 antagonist, in patients with WHIM syndrome. The study links pathway-directed treatment to longer periods of adequate neutrophil and lymphocyte counts and fewer infections, while leaving important questions about long-term safety, antibody responses, malignancy risk, and applicability unresolved.
-
SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis
2026-10-08
A 2023 study identifies SMYD2 as a pharmacologically tractable regulator of cisplatin-induced renal fibrosis and inflammation. Using AZ505 and LLY-507 in preclinical models, the authors connect SMYD2 inhibition with improved renal injury measures, reduced fibrotic and inflammatory signaling, and modulation of Smad3, STAT3, and Smad7 pathways.
-
WNT5a/GSK3/β-Catenin in FAP Adipogenesis
2026-10-08
The reference study identifies the WNT5a/GSK3/β-catenin axis as an important regulator of adipogenic drift in skeletal-muscle fibro/adipogenic progenitors (FAPs). By combining pharmacological, cytometric, transcriptomic, computational, ex vivo, and mouse-model evidence, it links β-catenin activity with reduced PPARγ-associated adipogenesis and improved support of muscle regeneration, while highlighting important limits to translation beyond the studied models.
-
Oteseconazole (VT-1161): Reading the Evidence
2026-10-07
Oteseconazole (VT-1161) is a selective tetrazole CYP51 inhibitor with activity across clinically relevant Candida species. This evidence-focused analysis explains what the data support, where translation remains uncertain, and why prevention of recurrent vulvovaginal candidiasis should be interpreted separately from emerging Candida auris research.
-
LY2603618 and Redox Control of CHK1 Sensitivity
2026-10-07
LY2603618 is a Chk1 inhibitor whose effects can be interpreted through replication stress, DNA damage signaling, and cell-cycle control. This article connects its reported cancer-model activity with new evidence that thioredoxin-dependent nucleotide metabolism may determine CHK1 inhibitor sensitivity.
-
TBXA2R–ERM Signaling in TNBC Metastasis
2026-10-06
Leguay et al. identify TBXA2R as an upstream GPCR activator of ERM proteins in triple-negative breast cancer cells, linking receptor signaling to motility, invasion, and metastatic colonization. The study defines a TBXA2R–Gαq/11–Gα12/13–Rho–SLK/LOK axis, while also showing why its findings should not yet be generalized to patients or unrelated cannabinoid receptor pathways.
-
Capture-and-Release Improves LFA Sensitivity
2026-10-05
A ChemRxiv study introduces AmpliFold, a capture-and-release strategy that temporarily sequesters antigen-bound complexes before triggered release and high-affinity rebinding in a lateral flow assay. In a HER2 model, the approach produced reported sensitivity improvements of up to 16-fold, although the evidence remains pre-peer-review and is limited to a defined assay architecture.
-
ALC-0159: Translational Lessons from Smarter LNPs
2026-10-04
A source-grounded analysis of how PEG-lipid context, endosomal escape, antigen expression and reactogenicity should be interpreted in translational mRNA-LNP research. The article places ALC-0159 alongside recent preclinical work on membrane-destabilizing zwitterionic lipids without conflating distinct formulation roles.
-
FGFR2-Targeted HDO and Asparagine Depletion in ICC
2026-10-03
The reference study describes a cholesterol-conjugated DNA/RNA heteroduplex oligonucleotide designed to selectively suppress the FGFR2-AHCYL1 fusion in intrahepatic cholangiocarcinoma. Its preclinical findings also identify an EGFR–STAT1–ASNS adaptation pathway, supporting further investigation of FGFR2-directed treatment together with asparagine restriction while underscoring the limits of xenograft evidence.
-
H2S Deficiency and ER Stress in Diabetic Cardiomyopathy
2026-10-02
Guo and colleagues identify reduced endogenous hydrogen sulfide production as a mechanistic contributor to lipid-induced myocardial injury in diabetic cardiomyopathy, linking H2S deficiency with endoplasmic reticulum stress, lipid accumulation, and cardiomyocyte apoptosis. By combining patient samples, a streptozotocin-induced rat model, and palmitate-treated cardiomyocytes, the study shows that H2S supplementation and ER-stress inhibition produce protective effects while also defining important considerations for spatially resolved H2S measurements.
-
EPZ5676: DOT1L Inhibitor Workflow Guide
2026-10-01
EPZ5676 is a highly selective DOT1L inhibitor for connecting biochemical target engagement with H3K79 methylation inhibition and MLL-rearranged leukemia models. This guide translates its potency, solvent profile, and selectivity into practical assay workflows, optimization checkpoints, and a cautious bridge to immunoepigenetic research.
-
Radiation-Altered Neuronal Differentiation via mGluR1
2026-10-01
The reference study shows that ionizing radiation can promote neuronal differentiation in C17.2 neural stem-like cells while altering the expression profile of neurotransmission-related genes. Its mechanistic analysis connects this phenotype to PI3K–STAT3–mGluR1 and PI3K–p53 signaling, providing a framework for studying radiation-associated brain dysfunction beyond neural stem-cell loss.
-
Aβ25-35: From Neurotoxicity to Translation
2026-09-30
Amyloid Beta-peptide (25-35) provides a focused experimental window into amyloid-driven neuronal injury, oxidative stress, mitochondrial dysfunction, and microglial activation. This thought-leadership perspective connects Aβ25-35 assay design with the FLOT1–FOSL2–EphA2 inflammatory axis to help translational researchers build more decision-ready Alzheimer’s disease models.
-
Z-VAD-FMK for Apoptosis and Ferroptosis
2026-09-30
Z-VAD-FMK helps separate caspase-dependent apoptosis from alternative regulated cell-death programs in immune, cancer, and adipose-cell models. This workflow-focused guide shows how to use it as a mechanistic control without misclassifying ferroptosis as apoptosis.